Related Experiment Videos
Pulmonary hypertension in beta-thalassemia
Athanasios Aessopos1, Dimitrios Farmakis
1First Department of Internal Medicine, University of Athens Medical School, Laiko General Hospital, 17 Aghiou Thoma St., Athens 115 27, Greece. aaisopos@cc.uoa.gr
Annals of the New York Academy of Sciences
|December 13, 2005
Summary
Pulmonary hypertension (PHT) is a serious complication in beta-thalassemia. Regular treatment prevents PHT in thalassemia major (TM), while it develops in thalassemia intermedia (TI) due to chronic hypoxia from inadequate treatment.
Area of Science:
- Cardiology
- Hematology
- Pulmonology
Background:
- Cardiac involvement, particularly pulmonary hypertension (PHT), is a major cause of mortality in beta-thalassemia major (TM) and thalassemia intermedia (TI).
- Previous studies showed conflicting evidence regarding PHT development in TM patients, possibly due to varied treatment protocols.
Purpose of the Study:
- To compare cardiac disease, specifically PHT, between uniformly treated TM and TI patients.
- To elucidate the role of chronic hypoxia in the pathophysiology of PHT in beta-thalassemia.
Main Methods:
- Comparison of cardiac disease in aged-matched groups of TM (n=131) and TI (n=74) patients.
- TM patients received regular transfusion and chelation therapy; TI patients received no specific treatment.
Main Results:
- Well-treated TM patients did not develop PHT, unlike TI patients.
- Systolic left ventricular dysfunction was observed only in TM patients.
- PHT in beta-thalassemia is linked to chronic tissue hypoxia, with different therapeutic approaches needed for TM and TI.
Conclusions:
- Regular, lifelong therapy in TM prevents PHT by eliminating chronic hypoxia.
- The absence of systematic treatment in TI leads to PHT development despite compensatory mechanisms for anemia.